SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Pictured: Regeneron logo on a light brown building
Drug Development
High Response Rate for Regeneron’s Myeloma Bispecific Marred by AEs
While almost half of multiple myeloma patients on linvoseltamab achieved a complete response or better, all experienced adverse events and 14 patients died due to treatment-emergent AEs.
December 7, 2023
 · 
2 min read
 · 
Kate Goodwin
Facade of Novo Nordisk's office in Fremont, California
Drug Development
Novo’s Wegovy Has Highest Adherence Rates in New Study of Weight-Loss Drugs
The study found only 19% of nearly 2,000 patients were still taking their prescribed anti-obesity medication at 12 months, compared to 40% that continued with Novo Nordisk’s Wegovy.
December 6, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Johnson & Johnson Sign/iStock, JHVEPhoto
J&J Expects Up to 6% Growth Next Year with 20-Plus New Drugs by 2030
Ten of the anticipated assets have the potential to deliver $5 billion or more in peak year sales, while another 15 of the candidates have a $1 billion to $5 billion PYS potential, according to Johnson & Johnson.
December 5, 2023
 · 
2 min read
 · 
Kate Goodwin
External view of AstraZeneca's headquarters building in Silicon Valley
Drug Development
AstraZeneca Axes Two Phase III Hyperkalemia Trials for Lokelma
Citing slow enrollment and low clinical rates, the late-stage “evidence trials” are being discontinued. AstraZeneca said there are no safety concerns and no impact on Lokelma’s current approved indication.
December 1, 2023
 · 
1 min read
 · 
Kate Goodwin
Pictured: Woman sitting on bed alone/iStock, Farkn
Xenon Looks to Raise Cash for MDD Program with $300M Public Offering
Despite a recent Phase II miss, Xenon Pharmaceuticals is forging ahead with its candidate for major depressive disorder, offering 8.4 million common shares for sale.
November 30, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Boehringer Ingelheim's office in California
Business
Boehringer Ingelheim Targets Stroma-Rich Cancers in Potential $509M AI Deal
The pharma giant is paying $9 million upfront to Phenomic AI to develop targets for stroma-rich cancers, some of the hardest cancers to treat, utilizing its single-cell RNA computing platform.
November 29, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Bristol Myers Squibb building in Munich/
Business
BMS Expands Cardio Partnership with Avidity in Potential $2.3B Deal
Building on a previous 2021 collaboration, Bristol Myers Squibb is paying $100 million upfront for the development of five cardiovascular targets utilizing Avidity Biosciences’ antibody oligonucleotide conjugates.
November 28, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Closed sign/iStock, StockSeller_UKR
Flagship-Founded Microbiome Company Evelo Biosciences Throws in the Towel
In an SEC filing, the biotech launched by Flagship Pioneering said there was no viable alternative to dissolution as its cash ran out and anti-inflammatory assets failed to achieve clinical success.
November 22, 2023
 · 
1 min read
 · 
Kate Goodwin
Pictured: Merck office building in Canada
Deals
Merck Drops Up to $610M on Neuro Disease-Focused Caraway Therapeutics
The buy brings three small molecules in preclinical development for Parkinson’s disease, amyotrophic lateral sclerosis and lysosomal storage diseases into Merck’s pipeline.
November 21, 2023
 · 
1 min read
 · 
Kate Goodwin
Pictured: Pfizer office at its South San Francisco
FDA
Pfizer, Astellas’ Xtandi Gets FDA Approval for Earlier Prostate Cancer Treatment
Xtandi is now approved to treat nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis with or without a gonadotropin-releasing hormone analog therapy.
November 17, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Astellas' Americas headquarters in Illin
Drug Development
Astellas Sees Path Forward for Gene Therapy Despite Four Patient Deaths
The Japanese pharma contends that an analysis of the four deaths in its AT132 gene therapy clinical trial shows it is still viable as a potential treatment for a fatal, rare genetic disease.
November 16, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Cancer cell surrounded by cytokines/iSto
Business
Alkermes Spins Off Oncology Business with $275M to Focus on Neuroscience
The new company, Mural Oncology, will continue registrational studies of its IL-2 cytokine in melanoma and ovarian cancer utilizing a $275 million cash runway expected to take them to the end of 2025.
November 15, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Novavax/Getty Images, STR/NurPhoto
Business
Novavax Q3 Revenue Slumps on Low Vaccination Rates, Trims 2023 Outlook
The vaccine maker is prepared to cut another $300 million in operating expenses in 2024 to keep the company afloat as it works to get its combination COVID-19/flu vaccine into Phase III.
November 9, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Bayer's office in New Jersey
Business
Bayer Eyes Break-Up, Management Cuts on Disappointing Q3 Results
The company on Wednesday reported nearly 50 billion euros, or $53.3 billion, in revenue with zero cash flow. Several layers of management will be eliminated as structural split-off strategies are considered.
November 8, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Downward arrow in graph showing stock price dropping
Drug Development
Ventyx Nixes Psoriasis Candidate Despite Positive Results, Stock Nosedives 75%
Although it hit primary and secondary endpoints in a Phase II study, Ventyx Biosciences concluded that the results weren’t strong enough to face the stiff competition for the indication.
November 7, 2023
 · 
2 min read
 · 
Kate Goodwin
Load More